High-density lipoprotein-cholesterol functionality and metabolic syndrome: Protocol for review and meta-analysis.


Journal Article

INTRODUCTION: The prevalence of metabolic syndrome (MetS) and MetS-related stroke is set to increase dramatically in coming decades. MetS is a complex disease that includes endothelial dysfunction, insulin resistance, diabetes, hypertension, ectopic obesity, and dyslipidaemia and an increased risk of cardiovascular events. One function of high-density lipoprotein (HDL) cholesterol (HDL-C) is the cholesterol-efflux pathway, which is the pathway where cholesterol is removed from macrophages within the arterial walls back into the bloodstream and out to the liver. As one of the key functions of HDL, their hypothesis was that if they could measure HDL-C-efflux capacity, they would have a better handle on the role of HDL in atherosclerosis. However, there are no systematic analyses or well-conducted meta-analyses to evaluate the relationship between HDL-C functionality and MetS. The aim of this study is to examine this association of HDL-C functionality with MetS in different ages and sex. METHODS AND ANALYSIS: The update systematic review and meta-analysis will be conducted using published studies that will be identified from electronic databases (i.e., PubMed, EMBASE, Web of Science, and Google Scholar). Studies that examined the association between HDL-C functionality and MetS; focused on cohort, case-control, and cross-sectional studies; were conducted among in adults aged 40 to 70 years; provided sufficient data for calculating odds ratio or relative risk with a 95% confidence interval; were published as original articles written in English or other languages; and have been published until January 2018 will be included. Study selection, data collection, quality assessment, and statistical syntheses will be conducted based on discussions among investigators. ETHICS AND DISSEMINATION: Ethics approval was not required for this study because it was based on published studies. The results and findings of this study will be submitted and published in a scientific peer-reviewed journal. TRIAL REGISTRATION NUMBER: PROSPERO (CRD42018083465).

Full Text

Duke Authors

Cited Authors

  • Roever, L; Resende, ES; Diniz, ALD; Penha-Silva, N; O'Connell, JL; Gomes, PFS; Zanetti, HR; Roerver-Borges, AS; Veloso, FC; Souza, FRD; Duarte, PRA; Fidale, TM; Casella-Filho, A; Dourado, PMM; Chagas, ACP; Ali-Hasan-Al-Saegh, S; Reis, PEO; Pinto, RDMC; Oliveira, GBF; Avezum, Á; Neto, M; Durães, AR; Silva, RMFLD; Grande, AJ; Denardi, C; Lopes, RD; Nerlekar, N; Alizadeh, S; Hernandez, AV; Rosa, MID; Biondi-Zoccai, G; Brazilian Network of Research in Meta-analysis (BRAMETIS),

Published Date

  • June 2018

Published In

Volume / Issue

  • 97 / 24

Start / End Page

  • e11094 -

PubMed ID

  • 29901625

Pubmed Central ID

  • 29901625

Electronic International Standard Serial Number (EISSN)

  • 1536-5964

Digital Object Identifier (DOI)

  • 10.1097/MD.0000000000011094


  • eng

Conference Location

  • United States